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A novel analytical method to detect the retention of gadolinium from contrast 25 
agents for magnetic resonance imaging (MRI) in tissue samples of patients is 26 
presented. It is based on laser ablation - inductively coupled plasma - triple 27 
quadrupole - mass spectrometry (LA-ICP-MS/MS). Both Gd and P were 28 
monitored with a mass shift of +16, corresponding to mono-oxygenated species, 29 
as well as Zn, Ca, and Fe on-mass. This method resulted in a significantly 30 
reduced background and improved limits of detection not only for phosphorus, 31 
but also for gadolinium. These improvements were essential to perform elemental 32 
bioimaging with improved resolution of 5 µm x 5 µm, allowing the detection of 33 
small Gd deposits in fibrotic skin and brain tumour tissue with diameters of 34 
approximately 50 µm. Detailed analyses of these regions revealed that most Gd 35 









The deposition of Gd originating from Gd-based contrast agents (GBCAs) in 41 
biological tissue has caused major concerns in the past decade. Grobner et al. 42 
first identified that Gd may be retained inside the body and may lead to a 43 
potentially fatal disease known as nephrogenic systemic fibrosis (NSF) [1]. NSF 44 
was first observed in patients with impaired renal function [2,3]. It took a further 45 
six years for the correlation of the development of NSF with the administration of 46 
GBCAs for magnetic resonance imaging (MRI) examinations conducted several 47 
years before [4]. Pathologies such as diffuse ulcerative calcific atherosclerosis, 48 
patchy myocardial necrosis, fibrosis and necrotic skin were also identified in 49 
patients with MRI history without renal dysfunction [5]. Kasahara et al. reported 50 
that Gd can be found in the dentate nucleus of MRI patients with a history of brain 51 
irradiation [6]. Xia et al. also identified Gd deposits in brain tumour samples 52 
obtained from five MRI patients without renal dysfunction by energy dispersive X-53 
ray spectroscopy (SEM/EDS), and demonstrated that the deposits also contained 54 
Ca and P [7], Ever since a FDA safety announcement in 2015 [8], the retention 55 
of Gd has attracted more concerns and triggered further investigations which 56 
were reviewed recently [9]. 57 
The development of NSF appears to be highly dependent on the type of the 58 
GBCA administered as different forms have disparate retention of Gd in the brain 59 
and other organs. Nevertheless, Gd retention in NSF and brain tissues has been 60 
reported for all categories (ionic/non-ionic, linear/macrocyclic) of GBCAs. Non-61 
ionic, linear GBCAs have been identified as the most problematic [10–13]. Birka 62 
et al. were able to show the presence of intact GBCAs in NSF skin biopsies of a 63 
patient by hydrophilic interaction liquid chromatography (HILIC) coupled to ICP-64 
MS, as well as confirm the deposition and accumulation of Gd with Ca and P of 65 
in NSF tissues by laser ablation-inductively coupled plasma-mass spectrometry 66 
(LA-ICP-MS) [14]. These results were subsequently confirmed by Roberts et 67 





Recently, Fingerhut et al. demonstrated the retention of Gd in specific brain 69 
regions of humans treated with GBCAs and located Gd in distinct cell types within 70 
these regions [16,17]. The pathogenesis of NSF as well as the mechanism of 71 
retention of Gd in specific brain regions such as the dentate nucleus still is largely 72 
unknown. Although GBCAs are considered to be thermodynamically stable and 73 
kinetically inert, it is hypothesised that Gd is released and precipitates, possibly 74 
together with calcium as (mixed) phosphate. Transmetallation reactions are 75 
suspected to play a crucial role for the release of Gd [5,18], as well as metabolism 76 
and elimination of GBCAs, which is compromised in patients with renal 77 
dysfunction [19]. The formation of small deposits of Gd and coprecipitation with 78 
Ca and P within various organs has been observed with imaging techniques such 79 
as element specific transmission electron microscopy (TEM), scanning electron 80 
microscopy/energy dispersive X-ray spectroscopy (SEM/EDX), secondary ion 81 
mass spectrometry (SIMS), synchrotron X-ray fluorescence (SXRF) and 82 
extended X-ray absorption fine structure (EXAFS) spectroscopy [7,19–27]. 83 
However, the relationship of these deposits and the pathogenesis of NSF has not 84 
been fully explored. One hypothesis is that circulating fibrocytes respond to the 85 
deposits to initiate fibrosis.[28]  86 
Accordingly, the investigation of the mechanism of NSF progression in relation to 87 
Gd deposits with diameters of approximately 50 µm requires a method that is 88 
capable of quantitative imaging with high spatial resolution and low limits of 89 
detection. Triple quadrupole technology for ICP-MS enhances the analysis of 90 
many elements by performing tandem mass spectrometry and was first 91 
hyphenated to a LA system in 2016 for elemental bioimaging [29]. Tandem mass 92 
spectrometry for ICP-MS has enhanced detection capabilities for many elements 93 
to improve detection limits and remove potential interferences. One approach to 94 
avoid spectral interferences is by shifting the analytes’ mass with favoured 95 
chemical reactions in the collision/reaction cell by adding a dedicated reaction 96 
gas. The selection of the reaction gas, the reaction conditions and the impact on 97 





al reviewed the theoretical background and recent applications, methods, theory 99 
and instrumentation [30,31]. 100 
In this work, we present a new method for the investigation of Gd deposition in a 101 
NSF skin sample as well as in a cancerous brain sample of a MRT patient by LA-102 
tandem ICP-MS. The limits of detection (LOD) for trace elements believed to play 103 
a key role in NSF, such as Gd, P, Ca, Fe and Zn, were compared against single 104 
quadrupole LA-ICP-MS to demonstrate the advantages of the LA-ICP-MS/MS 105 
method. 106 
1.1 Experimental 107 
1.1.1 Sample Preparation  108 
For elemental bioimaging (EBI), NSF samples were obtained from the “Johannes 109 
Wesling Klinikum” (hospital) in Minden in April 2013 and originate from a 25-year-110 
old female patient. A biopsy of an affected skin area was taken and immediately 111 
frozen to -20 °C. The patient showed typical NSF symptoms including swollen 112 
and sclerotic skin. The clinical history included a kidney transplantation and on-113 
going impaired renal function requiring regular dialysis. The patient underwent 114 
MRI examinations with the linear GBCA gadopentetate (Gd-DTPA, Bayer Vital 115 
(Leverkusen, Germany)) in 2002, and with the macrocyclic GBCA gadoteridol 116 
(Gd-HP-DO3A, Bracco Imaging, 0.5 M (Konstanz, Germany)) in 2005. The first 117 
symptoms appeared two years prior to the skin biopsy. For analysis, the skin 118 
sample was cut axially to 20 µm thickness using a cryotome (CryoStatTM NX70, 119 
Thermo Fisher Scientific) at -30 °C and placed onto glass slides. For a 120 
histological grading, a sequential slide was stained with hematoxylin and eosin 121 
(H&E) to visualise tissue structures. 122 
Brain tumour samples were obtained from the archives of the Institute of 123 
Neuropathology, University Hospital Münster and originated from a female 77 124 





WHO). She underwent an MRI examination with 20 mL of Gd-HP-DO3A. 126 
Samples were collected eleven days after the MRI examination during a biopsy 127 
and immediately frozen to -20 °C, cut to a thickness of 20 µm and mounted onto 128 
glass slides. 129 
For both patients, it should be noted that it cannot be excluded that they received 130 
Gd-based contrast agents prior to the treatment period which is documented 131 
above. Therefore, the Gd deposition detected in this work cannot be 132 
unambiguously traced back to the contrast agents, which are known to have been 133 
delivered. 134 
1.1.2 Calibration strategy 135 
Quantification of Gd and the determination of LODs of the elements of interest 136 
were performed by in-house prepared matrix-matched standards consisting of 137 
homogenised lamb brain spiked with respective elements and mounted in thin 138 
tissue sections with a thickness of 20 µm on glass slides. A detailed procedure 139 
for the fabrication, storage, quality control as well as the data analysis was 140 
already reported earlier by Hare et al. [32]. The matrix-matched standards were 141 
counter-quantified after digestion with 1 mL 30-32% H2O2 and 4 mL 70% HNO3 142 
(Seastar Baseline, Choice Analytical, Galveston, USA) using conventional liquid 143 
sample introduction with a 7500cx ICP-MS system (Agilent Technologies, 144 
Mulgrave, Victoria, Australia), shown in Table 1. The accuracy of the approach 145 
was validated using a BCR185R bovine liver reference standard.  146 
Table 1. Concentration levels of P, Ca, Fe, Zn and Gd present in the (matrix-matched) 147 
standards used for the generation of calibration curves and the subsequent 148 
determination of LODs. *In case of P, diluted standard solutions instead of spiked matrix 149 
samples were used for calibration. 150 




































1.1.3 Instrumentation and Tune Development  152 
For EBI, elements of interest were analysed with individual integration times on 153 
a 8800 series ICP-MS/MS system (Agilent Technologies, Mulgrave, Victoria, 154 
Australia) coupled to a New Wave Research NWR193 laser ablation unit 155 
(Kennelec Scientific, Mitcham, Victoria, Australia). (31P/31P16O: 50 ms, 44Ca: 156 
40 ms, 57Fe: 35 ms, 64Zn: 35 ms, 158Gd/158Gd16O, 47 ms). The single quadrupole 157 
(SQ) tune was developed according to Lear et al..[33] The laser scan speed and 158 
the spot size of the ArF excimer laser emitting nanosecond laser pulses at 159 
193 nm were adapted to generate squared pixels. For preliminary scans and 160 
comparison of LA-ICP-MS/MS against the LA-ICP-SQ-MS tunes, 50 µm laser 161 
beam spot size and 200 µm/s scan speed were chosen. For the high-resolution 162 
images, the parameters were adjusted to 5 µm and 20 µm/s, respectively. The 163 
sensitivity of the ICP-MS system was monitored on a daily basis and optimised 164 
with a tune solution containing 7Li, 89Y and 205Tl. A low oxide formation was 165 
guaranteed by monitoring the ThO/Th ratio (<0.3 %) and the P/A factor was 166 
adjusted before each measurement. For the MS/MS tune development, the 167 
ICP-MS/MS system was equipped with a MicroMist concentric nebuliser 168 
(Elemental Scientific, Omaha, NE, USA) and a Scott-type double-pass spray 169 
chamber (Glass Expansion, West Melbourne, Victoria, Australia). Using this 170 
liquid sample introduction system arrangement, plasma independent parameters 171 
were optimised to achieve lower LODs. Finally, dry plasma conditions were 172 
adapted for the operation of LA-ICP-MS. The initial tuning was performed by 173 
ablation of a NIST 612 “Trace Element in Glass” certified reference material 174 
(CRM), whereas the fine tuning was performed by monitoring the m/z of interest 175 
during the ablation of matrix-matched standards. The optimised tune parameters 176 





discrimination, -8 V; O2 cell gas flow, 0.32 mL/min; waiting time offset, 8 ms. To 178 
avoid long settling times caused by multiple filling and evacuation of the 179 
collision/reaction cell, all elements of interest were analysed with oxygen present 180 
as reaction gas. However, only P and Gd were monitored with a + 16 amu mass 181 
shift. In SQ mode, the first quadrupole was used as a band-pass filter and the 182 
ICP-MS/MS system provided the best figures of merit for all analytes when 183 
operating the collision/reaction cell with H2 gas flow of 3 mL/min [33]. To compare 184 
the figures of merit of both tunes, LODs were calculated based on the 3σ criterion 185 
by ablating line scans on matrix-matched tissue sections with a laser spot size of 186 
50 µm and a scan speed of 200 µm/s. The standard deviation was derived from 187 
the shutter blank and the respective sensitivities from five-point calibration 188 
curves. In the case of P, the natural background and the variations in matrix-189 
matched tissue derived from living organisms were too high for the estimation of 190 
the benefits of ICP-MS/MS over ICP-SQ-MS. Therefore, generation of a 191 
calibration curve for the determination of the LODs was conducted with diluted 192 
standard solutions on a liquid sample introduction system as described previously 193 
to demonstrate the advantages of the MS/MS tune. Quantification of high 194 
resolution data obtained using a laser beam spot size of 5 µm was solely 195 
conducted for Gd. A calibration curve was generated considering the standard 196 
deviations of each calibration point. The deviations were weighted according to 197 
equation 1. The deviation of 0 cps at a Gd concentration of 0 µg/g was weighted 198 
with 1.  199 
ω =  1
𝜎𝜎2
      (1) 200 
Where, ω is the weighting factor and σ is the standard deviation. The ICP-MS/MS 201 
system was operated with MassHunter software (Agilent Technologies). The LA 202 
unit was operated with ActiveView software (Electro Scientific Industries, 203 
Portland, Oregon, USA). The analytical figures of merit were processed using 204 
Origin software version 9 (OriginLab Corporation, Northhampton, MA, USA). 205 
Element images were generated using MassImager 3.17 software, an in-house 206 





1.2 Results and Discussion 208 
1.2.1 Tune Development for EBI 209 
On-mass or mass-shift MS/MS detection requires consideration of the reaction 210 
enthalpies. Both P and Gd have negative reaction enthalpies with O2 and were 211 
amenable for mass-shift monitoring at +16 amu. The remaining target elements 212 
Ca, Fe and Zn were monitored on-mass. Oxygen acted here as both reaction and 213 
collision gas. For the oxophilic elements P and Gd, mass shifting and tandem 214 
mass spectrometry resulted in a reduced background and therefore overall 215 
improved signal to noise ratios. The elements Ca, Zn and Fe showed improved 216 
figures of merit when analysed on-mass due to the collisional elimination of 217 
polyatomic interferents. The benefits of such detection modes for the elements 218 
were demonstrated via comparison of LODs against a standard ICP-SQ-MS 219 
method. The LODs were estimated by construction of calibration curves by LA 220 
line scans (50 µm spot size) of the matrix matched standards and application of 221 
the 3σ criterion or by estimation of the minimal detectable concentration (Figure 222 
1). In case of P, the determination of the LODs was performed via liquid standards 223 
as the matrix matched tissue standards had high backgrounds and variable 224 






Figure 1. Comparison of LODs obtained by (LA-)ICP-MS/MS and (LA-)ICP-SQ-MS. *In 227 
case of P, LODs were determined using a calibration curve obtained from diluted 228 
standards introduced via a liquid sample introduction system whereas the LODs of Gd, 229 
Fe, Ca and Zn originate from the dry plasma MS/MS tune performed in line-by-line scans 230 
on matrix-matched standards by LA-ICP-MS/MS.  231 
Due to highly abundant isobaric polyatomic interferents in the low mass range, 232 
the MS/MS tune for P resulted in a crucial improvement of 16.2-fold lower LODs. 233 
In case of Gd, the MS/MS tune eliminated the background to 0 cps, precluding 234 
the calculation of the LOD with the 3σ criterion. Instead, we used the lowest 235 
concentration (1.1 ng/g) that provided the least measurable signal (21 counts/s). 236 
This value was a 5.5-fold improvement compared against the ICP-SQ mode. For 237 
Fe, Ca and Zn, the ICP-MS/MS improvement factors were 28.3, 31.8, and 3.6, 238 
respectively. 239 
These improved LODs of the ICP-MS/MS were essential to successfully image, 240 
characterise and quantify the Gd deposits at higher resolutions of 5 µm. The 241 





1.2.2 NSF skin samples 243 
The large dimensions of the sample (approximately 3 cm x 0.8 cm) spanning 244 
various anatomical structures required a low resolution preliminary scan (pixel 245 
dimensions: 50 µm x 50 µm) to disclose regions of interest with dense 246 
distributions of Gd deposits. Figure 2 shows the quantitative distribution of Gd in 247 
the NSF skin sample and the corresponding microscopic image.  248 
Although there were hot spots of Gd deposits located throughout the sample 249 
(Figure 2), there were three areas of obvious accumulation, labelled (a), (b) and 250 
(c). Region of interest (a) had the most dense distribution of pixels with 251 
concentrations calculated via extrapolation to exceed 100 µg/g. Regions (b) and 252 
(c) consisted of a blood vessel and connective tissue, respectively, and had 253 
concentrations also exceeding 100 µg/g. Area (a) was targeted for further 254 







Figure 2. Comparison of the elemental Gd distribution and the corresponding 258 
microscopic image. Left: Quantitative Gd distribution obtained by LA-ICP-MS/MS with a 259 
spatial resolution of 50 µm. Three regions of interest are designated. Region (a) showed 260 
a distribution of hot spots in the sub cutis with concentrations exceeding 100 µg/g, (b) 261 
contains a blood vessel and (c) exhibits connective tissue in the deeper skin. Right: 262 
Corresponding microscopic image. 263 
Various layers of the skin within the region of interest were identified by a 264 
haematoxylin and eosin (H&E) stain of a consecutive section, which is shown in 265 
Figure 3. The epidermis is visible at (d), and fibrotic tissue at location (e) can be 266 
seen intermingled with fatty tissue areas (f). These histological findings are 267 






Figure 3. H&E stained NSF skin of a consecutive tissue section (corresponding to region 270 
of interest (a), shown in Figure 2). Different anatomical areas can be seen: epidermis 271 
(d), fatty tissue (f) and fibrotic tissue (e). 272 
A high-resolution (5 µm x 5 µm) LA-ICP-MS image of Gd, P, Ca, Fe and Zn, and 273 
a light photomicrograph of area (a) are shown in Figure 4. The improved 274 
resolution revealed hotspots of all target elements within small deposits of 275 
approximately 50 µm in the fibrotic tissue. The elemental distribution of Gd, P, Ca 276 
and Zn correlated in location and shape clearly demonstrating the abundance of 277 
insoluble phosphate species. Correlations with Fe were not observed. These 278 
observations were consistent with other investigations by SIMS [22], SXRF and 279 






Figure 4. A light microscopic image of NSF skin tissue (area a, Figure 3) and the 282 
elemental distributions of Gd, P, Ca and Zn. Except for Fe, all elements show strong 283 
correlations. 284 
Figure 5 presents a zoom view of area (a) to further visualise the composition of 285 
the deposits. Most of the Gd throughout the specimen was located within the 286 
deposits with the highest concentrations in the centre exceeding 100 µg/g. An 287 
overlay of Gd (green) and P (red) clearly shows co-localisation within the 288 
deposits. Similar correlations were found in accumulations for Ca and Zn. The 289 
most likely explanation for this distribution is the co-precipitation of Gd with 290 
calcium and zinc phosphate, when the concentration of the circulating free Gd 291 
and phosphate ions exceeds the solubility limits of Gd-phosphate (pKSP = 25.39). 292 
Only the core of the deposits is made of Gd whereas the shell seems to have an 293 
increasing fraction of P. This indicates that the Gd phosphate deposits may 294 







Figure 5. The Gd distribution in NSF skin tissue is shown and correlated to the distribution 298 
of P. Left: Zoomed views of the Gd distribution. The deposits contained most of the Gd 299 
found in the tissue sample. The centre of the deposits exhibited highest concentrations 300 
exceeding 100 µg/g. Right: Overlay of the 31P distribution (red) and the Gd distribution 301 
(green). Correlations are shown in yellow, showing smaller areas of Gd within P areas. 302 
1.2.3 Brain Tumour Samples  303 
Gd deposition in the brain was investigated in a brain biopsy originating from a 304 
patient with a glioblastoma tumour (IDH wildtype, grade IV WHO). Progression of 305 
glioblastoma is known to increase the permeability of the blood brain barrier due 306 
to localised damage. It was suspected that this patient’s tumour burden would 307 
lead to detectable deposits of Gd following administration of Gd-HP-DO3A. 308 
Figure 6 shows a 5 µm x 5 µm resolution image of the elemental distribution of 309 
the target elements in the brain tumour tissue. Like the deposits found in NSF 310 
skin tissue, the diameter was in the same range of approximately 50 µm x 50 µm 311 
or below. Correlations and co-localisation of Gd with P, Ca, Zn, as well as Fe 312 





factor of 25-100 times lower than in the skin biopsies. The concentration of Gd in 314 
the deposits exceeded 1 µg/g in some instances, whilst other accumulations had 315 
lower concentrations between 0.2 µg/g and 0.6 µg/g. 316 
 317 
 318 
Figure 6. Elemental distribution of Gd, P, Ca, Zn and Fe in a brain tissue section. The 319 
Gd distribution was calibrated using matrix-matched tissue standards. 320 
These results are in agreement with findings from Xia et al., who reported Gd 321 
deposits smaller than 50 µm inside brain tumours using SEM/EDX, and similar 322 
correlations with other elements.[7] Smaller deposits were reported in diseased 323 
brain tissue by McDonald et al..[23]  324 
Figure 7 presents a zoom view of the quantitative Gd distribution as well as an 325 
overlay of the P distribution and the Gd distribution. Both distributions correlated 326 
in terms of shape, dimensions and locations. These findings support preceding 327 
studies that reported the formation of insoluble deposits containing P, Ca, Fe and 328 
Zn. While such deposits in the brain seem to have very similar elemental 329 





concentration in the brain were significantly lower than determined in NSF skin 331 
tissue. 332 
 333 
Figure 7. Correlation of the Gd and P distribution in brain tissue. Left: Zoom view of the 334 
Gd distribution. The deposits contained most of the Gd in the brain tissue sample. The 335 
centre of the deposits exhibited highest concentrations exceeding 1 µg/g. Right: Overlay 336 
of the P distribution (red) and the Gd distribution (green). Correlations are shown in 337 
yellow showing a uniform distribution of P and 158Gd within the deposits. 338 
1.3 Conclusion 339 
The newly developed method was suitable for the quantification of various 340 
elements that are important for the investigation of Gd retention in patients who 341 
have undergone MRI diagnostics after administration of Gd-based contrast 342 
agents. Tandem mass spectrometry resulted in superior detection limits for Gd, 343 
P, Fe, Zn, and Ca when compared against a standard SQ based method for EBI. 344 
The improved detection tune was suitable for investigation of Gd depositions in 345 





distribution was quantified employing matrix matched tissue standards enabling 347 
the calibration of small Gd deposits, also observed in other studies, with 348 
diameters of approximately 50 µm for the first time. The analysis furthermore 349 
allowed the high spatial resolution of P, Zn, Ca and Fe and enabled the 350 
identification of correlations. The results support the hypothesis that Gd is 351 
liberated in a transmetallation process and precipitated as an insoluble 352 
phosphate salt. This method is a viable tool for analyses requiring higher 353 
resolutions or lower detection limits of elements taking part in the pathogenesis 354 
of NSF and the deposition of Gd in brain tissue. 355 
Acknowledgment 356 
Images were analysed and created using imaging software by Robin Schmid 357 
(University of Muenster). 358 
PAD is the recipient of an Australian Research Council Discovery Project 359 
(DP170100036). 360 
References 361 
[1] T. Grobner, Gadolinium - a specific trigger for the development of 362 
nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?, 363 
Nephrol. Dial. Transplant. 21 (2006) 1104–1108. doi:10.1093/ndt/gfk062. 364 
[2] S.E. Cowper, H.S. Robin, S.M. Steinberg, L.D. Su, S. Gupta, P.E. LeBoit, 365 
Scleromyxoedema-like cutaneous diseases in renal-dialysis patients, 366 
Lancet. 356 (2000) 1000–1001. doi:10.1016/S0140-6736(00)02694-5. 367 
[3] P. Marckmann, L. Skov, K. Rossen, A. Dupont, M.B. Damholt, J.G. Heaf, 368 
H.S. Thomsen, Nephrogenic systemic fibrosis: suspected causative role 369 
of gadodiamide used for contrast-enhanced magnetic resonance imaging, 370 
J. Am. Soc. Nephrol. 17 (2006) 2359–2362. 371 
[4] M. Birka, K.S. Wentker, E. Lusmöller, B. Arheilger, C.A. Wehe, M. 372 





Fibrosis by means of Elemental Bioimaging and Speciation Analysis, 374 
Anal. Chem. 87 (2015) 3321–3328. doi:10.1021/ac504488k. 375 
[5] S. Swaminathan, W.A. High, J. Ranville, T.D. Horn, K. Hiatt, M. Thomas, 376 
H.H. Brown, S. V. Shah, Cardiac and vascular metal deposition with high 377 
mortality in nephrogenic systemic fibrosis., Kidney Int. 73 (2008) 1413–378 
1418. doi:10.1038/ki.2008.76. 379 
[6] S. Kasahara, Y. Miki, M. Kanagaki, A. Yamamoto, N. Mori, T. Sawada, T. 380 
Taoka, T. Okada, K. Togashi, Hyperintense dentate nucleus on 381 
unenhanced T1-weighted MR images is associated with a history of brain 382 
irradiation., Radiology. 258 (2011) 222–228. doi:10.1148/radiol.10100508. 383 
[7] D. Xia, R.L. Davis, J.A. Crawford, J.L. Abraham, Gadolinium released 384 
from MR contrast agents is deposited in brain tumors: in situ 385 
demonstration using scanning electron microscopy with energy dispersive 386 
X-ray spectroscopy., Acta Radiol. 51 (2010) 1126–1136. 387 
doi:10.3109/02841851.2010.515614. 388 
[8] FDA Drug Safety Communication, FDA evaluating the risk of brain 389 
deposits with repeated use of gadolinium-based contrast agents for 390 
magnetic resonance imaging ( MRI ), (2015). 391 
[9] D. Clases, M. Sperling, U. Karst, Analysis of metal-based contrast agents 392 
in medicine and the environment, TrAC - Trends Anal. Chem. 104 (2018). 393 
135-147. doi:10.1016/j.trac.2017.12.011. 394 
[10] Y. Cao, D.Q. Huang, G. Shih, M.R. Prince, Signal change in the dentate 395 
nucleus on T1-weighted MR images after multiple administrations of 396 
gadopentetate dimeglumine versus gadobutrol, Am. J. Roentgenol. 206 397 
(2016) 414–419. doi:10.2214/AJR.15.15327. 398 
[11] N. Murata, L.F. Gonzalez-Cuyar, K. Murata, C. Fligner, R. Dills, D. Hippe, 399 
K.R. Maravilla, Macrocyclic and Other Non–Group 1 Gadolinium Contrast 400 





Invest. Radiol. 51 (2016) 447–53. doi:10.1097/RLI.0000000000000252. 402 
[12] A.P. Kartamihardja, T. Nakajima, S. Kameo, H. Koyama, Y. Tsushima, 403 
Impact of Impaired Renal Function on Gadolinium Retention After 404 
Administration of Gadolinium-Based Contrast Agents in a Mouse Model, 405 
Invest. Radiol. 51 (2016) 655–660. doi:10.1097/RLI.0000000000000295. 406 
[13] T.F. Flood, N. V Stence, J.A. Maloney, D.M. Mirsky, Pediatric Brain: 407 
Repeated Exposure to Linear Gadolinium-based Contrast Material Is 408 
Associated with Increased Signal Intensity at Unenhanced T1-weighted 409 
MR Imaging., Radiology. 282 (2016) 222–228. 410 
doi:10.1148/radiol.2016160356. 411 
[14] M. Birka, J. Roscher, M. Holtkamp, M. Sperling, U. Karst, Investigating 412 
the stability of gadolinium based contrast agents towards UV radiation, 413 
Water Res. 91 (2016) 244–250. doi:10.1016/j.watres.2016.01.012. 414 
[15] D.R. Roberts, S.M. Lindhorst, C.T. Welsh, K.R. Maravilla, M.N. Herring, 415 
A.K. Braun, B.H. Thiers, W.C. Davis, High Levels of Gadolinium 416 
Deposition in the Skin of a Patient With Normal Renal Function., Invest. 417 
Radiol. 51 (2016) 280–289. doi:10.1097/RLI.0000000000000266. 418 
[16] S. Fingerhut, A.-C. Niehoff, M. Sperling, A. Jeibmann, W. Paulus, T. 419 
Niederstadt, T. Allkemper, W. Heindel, M. Holling, U. Karst, Spatially 420 
resolved quantification of gadolinium deposited in the brain of a patient 421 
treated with gadolinium-based contrast agents, J. Trace Elem. Med. Biol. 422 
45 (2018) 125–130. doi:https://doi.org/10.1016/j.jtemb.2017.10.004. 423 
[17] S. Fingerhut, M. Sperling, M. Holling, T. Niederstadt, T. Allkemper, A. 424 
Radbruch, W. Heindel, W. Paulus, A. Jeibmann, U. Karst, Gadolinium-425 
based contrast agents induce gadolinium deposits in cerebral vessel 426 
walls, while the neuropil is not affected: an autopsy study, Acta 427 
Neuropathol. 136 (2018) 127–138. doi:10.1007/s00401-018-1857-4. 428 





targets, Magn. Reson. Imaging. 34 (2016) 1373-1376. 430 
doi:10.1016/j.mri.2016.08.016. 431 
[19] C. Thakral, J.L. Abraham, Gadolinium-induced nephrogenic systemic 432 
fibrosis is associated with insoluble Gd deposits in tissues: In Vivo 433 
transmetallation confirmed by microanalysis, J. Cutan. Pathol. 36 (2009) 434 
1244–1254. doi:10.1111/j.1600-0560.2009.01283.x. 435 
[20] S.J. George, S.M. Webb, J.L. Abraham, S.P. Cramer, Synchrotron X-ray 436 
analyses demonstrate phosphate-bound gadolinium in skin in 437 
nephrogenic systemic fibrosis, Br. J. Dermatol. 163 (2010) 1077–1081. 438 
doi:10.1111/j.1365-2133.2010.09918.x. 439 
[21] S.G. Schäd, P. Heitland, W.N. Kühn-Velten, G.E. Gross, L. Jonas, Time-440 
dependent decrement of dermal gadolinium deposits and significant 441 
improvement of skin symptoms in a patient with nephrogenic systemic 442 
fibrosis after temporary renal failure, J. Cutan. Pathol. 40 (2013) 935–944. 443 
doi:10.1111/cup.12214. 444 
[22] J.L. Abraham, S. Chandra, C. Thakral, J.M. Abraham, SIMS imaging of 445 
gadolinium isotopes in tissue from Nephrogenic Systemic Fibrosis 446 
patients: Release of free Gd from magnetic resonance imaging (MRI) 447 
contrast agents, Appl. Surf. Sci. 255 (2008) 1181–1184. 448 
doi:10.1016/j.apsusc.2008.05.140. 449 
[23] R.J. McDonald, J.S. McDonald, D.F. Kallmes, M.E. Jentoft, D.L. Murray, 450 
K.R. Thielen, E.E. Williamson, L.J. Eckel, Intracranial Gadolinium 451 
Deposition after Contrast-enhanced MR Imaging., Radiology. 275 (2015) 452 
772–82. doi:10.1148/radiol.15150025. 453 
[24] J.A. Schroeder, C. Weingart, B. Coras, I. Hausser, S. Reinhold, M. Mack, 454 
V. Seybold, T. Vogt, B. Banas, F. Hofstaedter, B.K. Krämer, 455 
Ultrastructural evidence of dermal gadolinium deposits in a patient with 456 





Soc. Nephrol. 3 (2008) 968–975. doi:10.2215/CJN.00100108. 458 
[25] C. Thakral, J. Alhariri, J.L. Abraham, Long-term retention of gadolinium in 459 
tissues from nephrogenic systemic fibrosis patient after multiple 460 
gadolinium-enhanced MRI scans: Case report and implications, Contrast 461 
Media Mol. Imaging. 2 (2007) 199–205. doi:10.1002/cmmi.146. 462 
[26] J.L. Abraham, C. Thakral, L. Skov, K. Rossen, P. Marckmann, Dermal 463 
inorganic gadolinium concentrations: Evidence for in vivo transmetallation 464 
and long-term persistence in nephrogenic systemic fibrosis, Br. J. 465 
Dermatol. 158 (2008) 273–280. doi:10.1111/j.1365-2133.2007.08335.x. 466 
[27] W.A. High, R.A. Ayers, J. Chandler, G. Zito, S.E. Cowper, Gadolinium is 467 
detectable within the tissue of patients with nephrogenic systemic fibrosis, 468 
J. Am. Acad. Dermatol. 56 (2007) 21–26. doi:10.1016/j.jaad.2006.10.047. 469 
[28] R.C. Semelka, M. Ramalho, M. AlObaidy, J. Ramalho, Gadolinium in 470 
humans: A family of disorders, Am. J. Roentgenol. 207 (2016) 229–233. 471 
doi:10.2214/AJR.15.15842. 472 
[29] D.P. Bishop, D. Clases, F. Fryer, E. Williams, S. Wilkins, D.J. Hare, N. 473 
Cole, U. Karst, P.A. Doble, Elemental bio-imaging using laser ablation-474 
triple quadrupole-ICP-MS, J. Anal. At. Spectrom. 31 (2016) 197–202. 475 
http://www.scopus.com/inward/record.url?eid=2-s2.0-476 
84952894964&partnerID=tZOtx3y1. 477 
[30] L. Balcaen, E. Bolea-Fernandez, M. Resano, F. Vanhaecke, Inductively 478 
coupled plasma - Tandem mass spectrometry (ICP-MS/MS): A powerful 479 
and universal tool for the interference-free determination of (ultra)trace 480 
elements - A tutorial review, Anal. Chim. Acta. 894 (2015) 7–19. 481 
doi:10.1016/j.aca.2015.08.053. 482 
[31] E. Bolea-Fernandez, L. Balcaen, M. Resano, F. Vanhaecke, Overcoming 483 
spectral overlap via inductively coupled plasma-tandem mass 484 





(2017) 1660–1679. doi:10.1039/C7JA00010C. 486 
[32] D.J. Hare, J. Lear, D. Bishop, A. Beavis, P.A. Doble, Protocol for 487 
production of matrix-matched brain tissue standards for imaging by laser 488 
ablation-inductively coupled plasma-mass spectrometry, Anal. Methods. 5 489 
(2013) 1915–1921. doi:10.1039/c3ay26248k. 490 
[33] J. Lear, D.J. Hare, F. Fryer, P.A. Adlard, D.I. Finkelstein, P.A. Doble, 491 
High-resolution elemental bioimaging of Ca, Mn, Fe, Co, Cu, and Zn 492 
employing LA-ICP-MS and hydrogen reaction gas, Anal. Chem. 84 (2012) 493 
6707–6714. doi:10.1021/ac301156f. 494 
 495 
